A Phase 1 Study of Cabiralizumab (BMS-986227, FPA008) Administered Alone or in Combination With Nivolumab (BMS-936558) in Advanced Malignancies

Trial Profile

A Phase 1 Study of Cabiralizumab (BMS-986227, FPA008) Administered Alone or in Combination With Nivolumab (BMS-936558) in Advanced Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Oct 2017

At a glance

  • Drugs Cabiralizumab (Primary) ; Nivolumab (Primary)
  • Indications Multiple myeloma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb; Ono Pharmaceutical
  • Most Recent Events

    • 11 Oct 2017 According to a Five Prime Therapeutics media release, preliminary safety, pharmacokinetic and pharmacodynamic data as well as initial efficacy data from one of the expansion cohorts will be presented at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting.
    • 30 Jun 2017 Status changed from not yet recruiting to recruiting.
    • 20 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top